Search

Your search keyword '"Serina-proteases"' showing total 2 results
Start Over Descriptor "Serina-proteases"
2 results on '"Serina-proteases"'

1. Pivotal role of AKT2 during dynamic phenotypic change of breast cancer stem cells

Author

[Gener P, Seras-Franzoso J, Perez A, Pindado LA, Casas G] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Rafael D] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Arango D] Investigació Biomèdica en Tumors de l'Aparell Digestiu, CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Fernández Y] Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Díaz-Riascos Z] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Abasolo I, Schwartz S] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain and Hospital Universitari Vall d'Hebron

Subjects
Serina-proteases, Enzimas y Coenzimas::Enzimas::Transferasas::Fosfotransferasas::Fosfotransferasas (Aceptor de Grupo Alcohol)::Proteínas Quinasas::Proteínas Serina-Treonina Quinasas::Proteína Serina-Treonina Quinasas de Interacción con Receptores::Proteína Serina-Treonina Quinasa 2 de Interacción con Receptor [COMPUESTOS QUÍMICOS Y DROGAS], Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::Receptor-Interacting Protein Serine-Threonine Kinases::Receptor-Interacting Protein Serine-Threonine Kinase 2 [CHEMICALS AND DRUGS], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Mama - Tumors, Cèl·lules canceroses, Neoplasias::Neoplasias por Localización::Neoplasias de la Mama [ENFERMEDADES], células::células madre::células madre neoplásicas [ANATOMÍA], Cells::Stem Cells::Neoplastic Stem Cells [ANATOMY]
Published
2021

2. Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells

Author

Simó Schwartz, Joaquin Seras-Franzoso, Anna Paradís Pérez, Ibane Abasolo, Petra Gener, Diego Arango, Luis Alamo Pindado, Yolanda Fernández, Glòria Casas, Diana Rafael, Zamira V. Díaz-Riascos, [Gener P, Seras-Franzoso J, Perez A, Pindado LA, Casas G] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Rafael D] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Arango D] Investigació Biomèdica en Tumors de l'Aparell Digestiu, CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Fernández Y] Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Díaz-Riascos Z] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Abasolo I, Schwartz S] Direccionament i alliberament farmacològic, Nanomedicina Oncologia molecular (CIBBIM-Nanomedicina), Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Àrea de Validació Funcional i Estudis Preclínics (FVPR), CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, Cancer Research, Small interfering RNA, Serina-proteases, dynamic phenotype, Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::Receptor-Interacting Protein Serine-Threonine Kinases::Receptor-Interacting Protein Serine-Threonine Kinase 2 [CHEMICALS AND DRUGS], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Epithelial-to-mesenchymal transition (EMT), neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], AKT2, Biology, Cells::Stem Cells::Neoplastic Stem Cells [ANATOMY], lcsh:RC254-282, Article, 03 medical and health sciences, 0302 clinical medicine, Circulating tumor cell, Breast cancer, Cancer stem cell, Cancer stem cells (CSC), Mama - Tumors, medicine, cancer stem cells (CSC), Dynamic phenotype, Mesenchymal stem cell, Cancer, AKT2 targeting, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, 030104 developmental biology, Oncology, enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-serina-treonina cinasas::proteínas serina-treonina cinasas de interacción con receptores::proteína serina-treonina cinasa 2 de interacción con receptor [COMPUESTOS QUÍMICOS Y DROGAS], 030220 oncology & carcinogenesis, Cancer research, Cèl·lules canceroses, células::células madre::células madre neoplásicas [ANATOMÍA], Stem cell, epithelial-to-mesenchymal transition (EMT)
Abstract

Cancer stem cells (CSC); Dynamic phenotype; Epithelial-to-mesenchymal transition (EMT) Células madre cancerosas (CSC); Fenotipo dinámico; Transición epitelial a mesenquimal (EMT) Cèl·lules mare canceroses (CSC); Fenotip dinàmic; Transició epitelial a mesenquimal (EMT) Therapeutic resistance seen in aggressive forms of breast cancer remains challenging for current treatments. More than half of the patients suffer from a disease relapse, most of them with distant metastases. Cancer maintenance, resistance to therapy, and metastatic disease seem to be sustained by the presence of cancer stem cells (CSC) within a tumor. The difficulty in targeting this subpopulation derives from their dynamic interconversion process, where CSC can differentiate to non-CSC, which in turn de-differentiate into cells with CSC properties. Using fluorescent CSC models driven by the expression of ALDH1A 1(aldehyde dehydrogenase 1A1), we confirmed this dynamic phenotypic change in MDA-MB-231 breast cancer cells and to identify Serine/Threonine Kinase 2 (AKT2) as an important player in the process. To confirm the central role of AKT2, we silenced AKT2 expression via small interfering RNA and using a chemical inhibitor (CCT128930), in both CSC and non-CSC from different cancer cell lines. Our results revealed that AKT2 inhibition effectively prevents non-CSC reversion through mesenchymal to epithelial transition, reducing invasion and colony formation ability of both, non-CSC and CSC. Further, AKT2 inhibition reduced CSC survival in low attachment conditions. Interestingly, in orthotopic tumor mouse models, high expression levels of AKT2 were detected in circulating tumor cells (CTC). These findings suggest AKT2 as a promising target for future anti-cancer therapies at three important levels: (i) Epithelial-to-mesenchymal transition (EMT) reversion and maintenance of CSC subpopulation in primary tumors, (ii) reduction of CTC and the likelihood of metastatic spread, and (iii) prevention of tumor recurrence through inhibition of CSC tumorigenic and metastatic potential. This work was funded by Fondo de Investigaciones Sanitarias (FIS) from ISCIII, Spanish ministry of Economy and Competitiveness, grant PI17/02242 co-financed by The European Regional Development Fund (FEDER); AC15/00092 grant (Target4Cancer project) from Euro-NanoMed II and PENTRI project, financed by Marato TV3, and EvoNano project, funded by European Union's Horizon 2020 FET Open programme under grant agreement. No. 800983. JSR was supported by a post-doctoral grant from Asociacion Espanola Contra el Cancer (AECC).

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results